ArticlePneumonia (Nathan Qld.)2026
Antibiotic non-susceptibility associated serotypes of invasive pneumococcal disease - a nationwide population study from Switzerland, 2012-2022.
Article in Pneumonia (Nathan Qld.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt has been reported that the introduction of thirteen-valent pneumococcal conjugate vaccine (PCV13) had an influence on antibiotic resistance rates of invasive pneumococcal disease (IPD). Recent data about antibiotic resistance in IPD are scarce. The aim of the current study was to analyse the impact of PCV13 introduction and COVID-19 pandemic on antibiotic resistance in IPD and the effects of antibiotic resistance on mortality. Furthermore, we correlate vaccine and non-vaccine serotypes with antibiotic resistance.
methodsWe included 8747 IPD cases from a Swiss nationwide IPD surveillance database for 2012-2022. Regression analyses were performed to examine significant trends over time and to identify serotypes and patient characteristics associated with antibiotic resistance.
resultsThe proportion of non-susceptibility to erythromycin (IRR: 0.9, p < 0.001) and cotrimoxazole (IRR: 0.9, p < 0.001) decreased from 2012 to 2022. Penicillin non-susceptibility remained constant with a dip in 2022 (2012: 9.2%, 2022: 4.7%). PCV13 serotypes 6B, 9V, 14, 19A and 19F were significantly associated with non-susceptibility while the non-PCV13 serotype 15A, 23B, 24/F and 6C were associated with resistance to at least two antibiotic groups. Antibiotic non-susceptibility was not associated with death but meningitis was associated with penicillin non-susceptibility.
conclusionsAntibiotic resistance in IPD decreased over time without increases during the COVID-19 pandemic, while a strong association between serotypes and antibiotic resistance persists. Introduction of vaccines with extended serotype coverage may further affect antibiotic resistance rates underlining the importance of continued surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.